Baron Asset Fund (BARAX)

Portfolio Management

Andrew Peck

Fund Manager since 2003

View All Commentary by Andrew

Fund Description

Baron Asset Fund invests primarily in mid-sized growth companies.


Portfolio Commentary

Retail Performance

Review and Outlook (for quarter ended 6/30/2015)

During the three-month period ended June 30, 2015, Baron Asset Fund gained 0.76%, the Russell Midcap Growth Index declined 1.14%, and the S&P 500 Index gained 0.28%.

The Fund’s positive return was driven by strong performance among several health care-related companies, including Illumina, Inc., a leading technology provider to the DNA sequencing market, and Universal Health Services, Inc., an operator of acute care and behavioral health hospitals. In addition, Pall Corp., a filtration technology company with significant customers in the health care industry, agreed to sell itself at a large premium. Financial Services holdings also did well, as Arch Capital Group, Ltd rose on merger speculation in the insurance industry, and Charles Schwab Corp. benefited from rising interest rates during the period. Rising commodity prices during the quarter were a positive driver of the Fund’s Energy sector holdings, including Shell Midstream Partners LP. Laggards included several companies that missed earnings expectations for company-specific reasons, including veterinary diagnostic firm IDEXX Laboratories, Inc. and social network LinkedIn Corp. The hotel sub-industry also lagged, as Choice Hotels International, Inc. and Hyatt Hotels Corp. detracted from results. Despite continued strong financial results, Hyatt lost ground as a result of investor concerns over a potential slowdown in the lodging cycle, as well as muted travel to South Korea in reaction to the MERS virus outbreak.

During the quarter we initiated a position in the newly issued Tallgrass Energy GP, LP, the general partner of a fast-growing master limited partnership. Tallgrass has an interest in various assets that transport, store and process natural gas and crude oil, primarily in the Appalachian Basin. We have been following this company (and its management team) for a long time through our Firm’s investment in Tallgrass Energy Partners, LP, which is led by many of the same executives. We have high conviction in the ability of Tallgrass Energy GP to grow its cash distributions at a rapid pace for the foreseeable future through its economic interest in the cash flow streams of high-quality infrastructure assets with limited exposure to commodity price and volume risk.

Nothing has changed our longstanding view that high-quality, mid-sized growth stocks represent an attractive investment opportunity. The U.S. economy remains among the world’s healthiest, its equity market multiples remain within the range of their long-term historic averages, and we expect that interest rates will continue to remain quite low by historic standards.  Employment and housing trends continue to improve, and energy prices remain meaningfully below their recent levels. We believe that our portfolio of well-managed, competitively advantaged, fast growing companies will continue to perform well in this environment.

Top Contributors/Detractors to Performance

Contributors (for quarter ended 6/30/2015)
  • Illumina, Inc. is the leading provider of next generation DNA sequencing instruments and consumables. Shares rose on reports of better-than-expected revenue and earnings driven by strong sales of sequencing instruments. We maintain conviction because we believe Illumina holds a monopoly on DNA sequencing at a time when DNA sequencing is increasingly being used in cancer research and diagnosis and reproductive health.

  • Shares of Universal Health Services, Inc., a leading operator of acute care hospitals and the U.S.’s largest provider of behavioral health services, jumped in late June in response to the U.S. Supreme Court’s decision to uphold subsidies on federal exchanges under the Affordable Care Act, effectively shutting down legal challenges to the law which is expanding insurance coverage to millions of Americans. This positive outcome came on the heels of a solid Q1 beat as the improving macro economy drives strengthening operating performance.

  • Pall Corp. is a leading supplier of filtration, separation, and purification technologies to life sciences and industrial customers. On May 13, Pall agreed to be acquired by Danaher Corporation for $127.20 per share, which represented a 28% premium over the closing price on the day prior to media speculation about a possible sale of the company. We sold our position after the stock appreciated in response to the announced sale.

Detractors (for quarter ended 6/30/2015)
  • After several quarters of strong performance, shares of veterinary diagnostics leader IDEXX Laboratories, Inc. fell in Q2. We attribute a portion of the stock’s decline to greater-than-expected foreign exchange headwinds. Separately, the company noted increased competition and lower prices, impacting around 3% of revenue. We believe management will respond successfully with pricing programs, creative diagnostic bundles, and an expanded inside sales force to better serve its customers.

  • Shares of Choice Hotels International, Inc., a franchisor of economy hotel rooms, decreased in Q2 as slightly slower-than-expected growth in revenue per available room (RevPAR) and a high multiple stock led to investor sales. We believe the company has growth potential, driven by its recent revamp of the Comfort brand, continued increases in RevPAR, and stronger unit growth as owners see value in the Choice brands and sign new contracts. The company generated strong cash flow that it used for growth initiatives and dividends in Q2.

  • LinkedIn Corp. is the #1 professional networking platform with over 350 million registered members. Shares were pressured by noisy Q1 results, where the company lowered guidance due to foreign exchange rates, an internal sales force transition, display advertising weakness, and the unexpected accounting treatment of a recent acquisition. We believe LinkedIn is a unique platform asset in the early days of capturing a $27 billion talent acquisition market and a $25 billion B2B advertising market, with interesting upside optionality.

Quarterly Attribution Analysis (for quarter ended 6/30/2015)

The Quarterly Attribution Analysis for period ending June 30, 2015 is not yet available

Back to Top

Invest In Baron Funds Today

The prospective performance of the companies discussed herein is based on our internal analysis and reflect our opinions only. We cannot promise future returns and our opinions are a reflection of our best judgment at the time of publication. Our views are not intended as recommendations or investment advice to any person and are subject to change at any time based on market and other conditions and Baron has no obligation to update them. Investing in the stock market is always risky. Current and future portfolio holdings in the Baron Funds are subject to risk.